CTRI/2009/091/000134已完成2 期
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes
ovartis Healthcare Private Limited0 个研究点目标入组 452 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 452
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •?Patients at least 18 years of age at Visit 1
- •?Drug naïve patients with T2DM diagnosed at least 2 months prior to Visit 1
- •?HbA1c ≥ 7.0 % and ≤ 10.0% at Visit 1
- •?Body Mass Index (BMI) in the range of 22-45 kg/m2 at Visit 1
排除标准
- •?Pregnant or lactating female
- •?FPG ≥ 270 mg/dL (≥15 mmol/L)
研究者
相似试验
进行中（未招募）
不适用
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetesEUCTR2008-004722-16-GBovartis Pharma Services AG2,500
已完成
不适用
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes-E11 Non-insulin-dependent diabetes mellitusNon-insulin-dependent diabetes mellitusE11PER-012-09OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
1 期
International clinical study to compare cadazolid to vancomycin to treatCDADEUCTR2013-002528-17-DEActelion Pharmaceuticals Ltd630
进行中（未招募）
1 期
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetesType II DiabetesEUCTR2008-004722-16-SKovartis Pharma Services AG2,500
进行中（未招募）
不适用
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetesType II DiabetesEUCTR2008-004722-16-LVovartis Pharma Services AG2,500